We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
Read MoreHide Full Article
Inovio Pharmaceuticals, Inc. (INO - Free Report) announced that it has initiated a phase Ib/II study to evaluate the combination of two immunotherapy candidates and Roche Holding AG’s (RHHBY - Free Report) anti-PDL1 inhibitor, Tecentriq in advanced bladder cancer. Inovio’s candidates include INO-5401, a T cell activating immunotherapy and INO-9012, an immune activator.
The study will specially focus on advanced unresectable or metastatic urothelial carcinoma ("UC"), which is the most common form of bladder cancer.
Shares of the company have lost 10.6% so far this year, underperforming the industry’s gain of 12.4% in the period.
The multi-center study will be conducted by Inovio and Roche will be responsible for supplying Tecentriq for the study through its subsidiary Genentech. The study is expected to enroll 80 patients approximately with majority having received prior treatment with an anti-PD-1 or PD-L1 checkpoint inhibitor but failing to achieve meaningful response.
Inovio will evaluate the potential benefit of treating advanced bladder cancer through a combination of a checkpoint inhibitor, a DNA-based immunotherapeutic and a T cell activator. The study will also provide more information on how the immune system works in a bladder cancer patient on T cell activation and checkpoint inhibition.
Although multiple checkpoint inhibitors are approved for treating UC, only a small number of patients are responsive to them. An associate professor at Harvard Medical School believes that the combination of checkpoint inhibitor with T cell activator will bring significant improvements.
INO-5401 activates T cell for multiple types of cancer including bladder cancer and INO-9012 helps to increase and accelerate T cell immune responses to INO-5401.
Per the recent press release, it is estimated that almost 430,000 are diagnosed with bladder cancer with 165,000 deaths worldwide every year. With high unmet medical need in UC, a new therapy with improved response and survival rates and impacting a large section of the population will be welcomed by the medical community.
Inovio carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Ligand Pharmaceuticals Incorporated (LGND - Free Report) and Exact Sciences Corporation (EXAS - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have remained stable for 2017 and increased from $3.68 to $3.70 for 2018 over the last 30 days. The company delivered positive earnings surprise in two of the trailing four quarters, with an average beat of 6.19%. Share price of the company has increased 49.5% year to date.
Exact Sciences’ loss estimates have remained stable for 2017 and 2018 over the 30 days. The company came up with positive earnings surprise in three of the trailing four quarters, with an average beat of 38.75%. The share price of the company has increased 253.3% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
Inovio Pharmaceuticals, Inc. (INO - Free Report) announced that it has initiated a phase Ib/II study to evaluate the combination of two immunotherapy candidates and Roche Holding AG’s (RHHBY - Free Report) anti-PDL1 inhibitor, Tecentriq in advanced bladder cancer. Inovio’s candidates include INO-5401, a T cell activating immunotherapy and INO-9012, an immune activator.
The study will specially focus on advanced unresectable or metastatic urothelial carcinoma ("UC"), which is the most common form of bladder cancer.
Shares of the company have lost 10.6% so far this year, underperforming the industry’s gain of 12.4% in the period.
The multi-center study will be conducted by Inovio and Roche will be responsible for supplying Tecentriq for the study through its subsidiary Genentech. The study is expected to enroll 80 patients approximately with majority having received prior treatment with an anti-PD-1 or PD-L1 checkpoint inhibitor but failing to achieve meaningful response.
Inovio will evaluate the potential benefit of treating advanced bladder cancer through a combination of a checkpoint inhibitor, a DNA-based immunotherapeutic and a T cell activator. The study will also provide more information on how the immune system works in a bladder cancer patient on T cell activation and checkpoint inhibition.
Although multiple checkpoint inhibitors are approved for treating UC, only a small number of patients are responsive to them. An associate professor at Harvard Medical School believes that the combination of checkpoint inhibitor with T cell activator will bring significant improvements.
INO-5401 activates T cell for multiple types of cancer including bladder cancer and INO-9012 helps to increase and accelerate T cell immune responses to INO-5401.
Per the recent press release, it is estimated that almost 430,000 are diagnosed with bladder cancer with 165,000 deaths worldwide every year. With high unmet medical need in UC, a new therapy with improved response and survival rates and impacting a large section of the population will be welcomed by the medical community.
Inovio Pharmaceuticals, Inc. Price and Consensus
Inovio Pharmaceuticals, Inc. Price and Consensus | Inovio Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Inovio carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Ligand Pharmaceuticals Incorporated (LGND - Free Report) and Exact Sciences Corporation (EXAS - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have remained stable for 2017 and increased from $3.68 to $3.70 for 2018 over the last 30 days. The company delivered positive earnings surprise in two of the trailing four quarters, with an average beat of 6.19%. Share price of the company has increased 49.5% year to date.
Exact Sciences’ loss estimates have remained stable for 2017 and 2018 over the 30 days. The company came up with positive earnings surprise in three of the trailing four quarters, with an average beat of 38.75%. The share price of the company has increased 253.3% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>